Zoetis Inc. $ZTS Shares Purchased by UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC

Key Points

• UBS Asset Management increased its stake in Zoetis Inc. by 4.3%, resulting in ownership of approximately 4.25 million shares valued at $700 million, according to its latest SEC filing.
• Zoetis reported earnings of $1.76 per share, exceeding the consensus estimate of $1.62, with quarterly revenue of $2.46 billion, a 4.2% increase from the previous year.
• Wall Street analyst ratings for Zoetis are mixed, with some downgrading their ratings while others maintain a buy, leading to a consensus rating of "Moderate Buy" and an average price target of $200.88.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 4.3% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,252,697 shares of the company's stock after buying an additional 174,119 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned 0.96% of Zoetis worth $700,207,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of ZTS. 1248 Management LLC purchased a new position in Zoetis during the first quarter worth $27,000. Saudi Central Bank purchased a new position in Zoetis during the first quarter worth $29,000. Cornerstone Planning Group LLC increased its position in Zoetis by 79.3% during the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock worth $30,000 after buying an additional 88 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its position in Zoetis by 87.6% during the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock worth $42,000 after buying an additional 120 shares in the last quarter. Finally, Sound Income Strategies LLC increased its position in Zoetis by 141.4% during the first quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock worth $46,000 after buying an additional 164 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Analysts Set New Price Targets

ZTS has been the subject of several recent research reports. Leerink Partners downgraded Zoetis from an "outperform" rating to a "market perform" rating and dropped their price target for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Leerink Partnrs downgraded Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Argus restated a "buy" rating and set a $190.00 price objective on shares of Zoetis in a report on Tuesday. Finally, Piper Sandler raised their price objective on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a report on Monday, August 11th. Five equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, Zoetis presently has a consensus rating of "Moderate Buy" and a consensus price target of $200.88.

Zoetis Trading Down 1.5%

Shares of ZTS stock traded down $2.28 during mid-day trading on Friday, hitting $148.33. 3,111,229 shares of the company's stock were exchanged, compared to its average volume of 2,278,915. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The stock has a 50-day simple moving average of $152.32 and a two-hundred day simple moving average of $157.31. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The stock has a market cap of $65.74 billion, a price-to-earnings ratio of 25.53, a PEG ratio of 2.42 and a beta of 0.89.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.46 billion for the quarter, compared to analysts' expectations of $2.41 billion. During the same quarter last year, the firm earned $1.56 earnings per share. The firm's revenue for the quarter was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.